Drugs / SHR20004
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT06137469 | Dec 2023 → Mar 2024 | type 2 diabetes mellitus | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT05031871 | Sep → Nov 2021 | type 2 diabetes mellitus | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04799327 | Mar 2021 → May 2022 | obesity disorder | Jiangsu HengRui Medicine Co., Ltd. | Unknown | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05333835 Comparator | Jul 2022 → Mar 2024 | type 2 diabetes mellitus | Jiangsu HengRui Medicine Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SHR20004 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04799327 ↗ |
| Route | Subcutaneous | “Multiple Subcutaneous Injections of SHR20004” NCT06137469 ↗ |